Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis

Allergy and Asthma Proceedings, 05/15/2012

This clinical study indicated that treatment with beclomethasone dipropionate (BDP) nasal aerosol provides statistically significant and clinically meaningful nasal symptom relief accompanied by improved quality of life in subjects with persistent allergic rhinitis (PAR). Additionally, treatment with BDP nasal aerosol was well tolerated with a safety profile comparable to that of placebo.

Print Article Summary Cat 2 CME Report